These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7519674)

  • 1. Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the Canadian Open ddI Treatment Program.
    Montaner JS; Rachlis A; Beaulieu R; Gill J; Schlech W; Phillips P; Auclair C; Boulerice F; Schindzielorz A; Smaldone L
    J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):924-30. PubMed ID: 7519674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Didanosine therapy in patients intolerant of or failing zidovudine therapy.
    Rathbun RC; Martin ES
    Ann Pharmacother; 1992 Nov; 26(11):1347-51. PubMed ID: 1362093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Italian multicentre study of didanosine compassionate use in advanced HIV infection. Italian BMS-906 Study Group.
    d'Arminio Monforte A; Musicco M; Galli M; Paga C; La Regina A; Lazzarin A; Angarano G; Milazzo F; Gritti F; Arlotti M; Mazzotta F; Visco G; Aiuti F; Moroni M
    Eur J Clin Microbiol Infect Dis; 1997 Feb; 16(2):135-42. PubMed ID: 9105840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. German ddI Trial Group.
    Jablonowski H; Arasteh K; Staszewski S; Ruf B; Stellbrink HJ; Schrappe M; Stoehr A; Haase W; Schomaker U; von Eisenhart Rothe B
    AIDS; 1995 May; 9(5):463-9. PubMed ID: 7639971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
    McKinney RE; Johnson GM; Stanley K; Yong FH; Keller A; O'Donnell KJ; Brouwers P; Mitchell WG; Yogev R; Wara DW; Wiznia A; Mofenson L; McNamara J; Spector SA
    J Pediatr; 1998 Oct; 133(4):500-8. PubMed ID: 9787687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot case-control study of zidovudine compared with zidovudine plus didanosine in patients with advanced HIV-1 disease and no previous experience with antiretrovirals.
    Gatell JM; Leal M; Mallolas J; Vidal C; Pumarola T; Parra R; Padró S; Caruz A; Falgueras T; Rey C; Sánchez-Quijano A; Torres Y; Lissen E; Jiménez de Anta MT; Soriano E
    Antivir Ther; 1996 Apr; 1(2):105-12. PubMed ID: 11321180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized study of didanosine monotherapy and combination therapy with zidovudine in hemophilic and nonhemophilic subjects with asymptomatic human immunodeficiency virus-1 infection. AIDS Clinical Trial Groups.
    Ragni MV; Amato DA; LoFaro ML; DeGruttola V; Van Der Horst C; Eyster ME; Kessler CM; Gjerset GF; Ho M; Parenti DM
    Blood; 1995 May; 85(9):2337-46. PubMed ID: 7727768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with ZDV + DDI versus ZDV + DDC in patients with progression of HIV-infection under treatment with ZDV.
    Mauss S; Adams O; Willers R; Jablonowski H
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(5):469-77. PubMed ID: 8605592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group.
    Gatell JM; González-Lahoz J; Clotet B; Antunes F; Kasparova L; Gil-Aguado A; Saballs P; Santamaria JM; Podzamczer D; Miro JM; Jou A; Verdejo J; Doroana M; Thomis J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):249-58. PubMed ID: 8673528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine.
    Connolly KJ; Allan JD; Fitch H; Jackson-Pope L; McLaren C; Canetta R; Groopman JE
    Am J Med; 1991 Nov; 91(5):471-8. PubMed ID: 1659189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group.
    Montaner JS; Schechter MT; Rachlis A; Gill J; Beaulieu R; Tsoukas C; Raboud J; Cameron B; Salomon H; Dunkle L; Smaldone L; Wainberg MA
    Ann Intern Med; 1995 Oct; 123(8):561-71. PubMed ID: 7677296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial (ISS 902) of didanosine versus zidovudine in previously untreated patients with mildly symptomatic human immunodeficiency virus infection.
    Floridia M; Vella S; Seeber AC; Tomino C; Fragola V; Weimer LE; Ricciardulli D; Milazzo F; Gritti FM; Mazzotta F; Ranieri S; Chiodo F; Moroni M; Cargnel A; Bassetti D; Giannini V; Cremoni L; Concia E; Sinicco A; Carosi G; Alberici F; Dianzani F
    J Infect Dis; 1997 Feb; 175(2):255-64. PubMed ID: 9203645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Alpha trial: European/Australian randomized double-blind trial of two doses of didanosine in zidovudine-intolerant patients with symptomatic HIV disease. Alpha International Coordinating Committee.
    AIDS; 1996 Jul; 10(8):867-80. PubMed ID: 8828744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for prolonged clinical benefit from initial combination antiretroviral therapy: Delta extended follow-up.
    Delta Coordinating Committee
    HIV Med; 2001 Jul; 2(3):181-8. PubMed ID: 11737399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of didanosine administered orally twice daily to patients with advanced human immunodeficiency virus infection and hematologic intolerance of zidovudine.
    Allan JD; Connolly KJ; Fitch H; Jackson-Pope L; McLaren C; Canetta R; Groopman JE
    Clin Infect Dis; 1993 Feb; 16 Suppl 1():S46-51. PubMed ID: 8425019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT).
    Moyle GJ; Nelson MR; Hawkins D; Gazzard BG
    Q J Med; 1993 Mar; 86(3):155-63. PubMed ID: 8387218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.
    Englund JA; Baker CJ; Raskino C; McKinney RE; Petrie B; Fowler MG; Pearson D; Gershon A; McSherry GD; Abrams EJ; Schliozberg J; Sullivan JL
    N Engl J Med; 1997 Jun; 336(24):1704-12. PubMed ID: 9182213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Didanosine.
    Shelton MJ; O'Donnell AM; Morse GD
    Ann Pharmacother; 1992 May; 26(5):660-70. PubMed ID: 1350471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.
    Kovacs A; Cowles MK; Britto P; Capparelli E; Fowler MG; Moye J; McIntosh K; Rathore MH; Pitt J; Husson RN
    Pediatr Infect Dis J; 2005 Jun; 24(6):503-9. PubMed ID: 15933559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zidovudine therapy and HIV type 1 mutations in children with symptomatic HIV type 1 infection: effect of switching to didanosine or zidovudine plus didanosine therapy. Italian Multicenter Study Group on HIV Mutations in Children.
    Principi N; Marchisio P; Esposito S; Rossi P; Gattinara GC; Galli L; Gabiano C; Zuccotti GV; Orlandi P
    AIDS Res Hum Retroviruses; 1998 Dec; 14(18):1653-9. PubMed ID: 9870319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.